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Introduction: Familial amyloid polyneuropathy is a group of autosomal dominant disorders characterized by
extracellular amyloid deposition in several target organs. This paper aims to report an unusual manifestation of
retinal vascular leakage including optic disc and macular edema in a patient with familial amyloid polyneuropathy.
Case presentation: A 37-year-old Portuguese Caucasian man with Val30Met transthyretin-related familial amyloid
polyneuropathy presented with rapidly progressing visual loss in his left eye. He had undergone liver transplantation
at the age of 30 with neurologic stabilization. Fundoscopy and fluorescein angiogram revealed optic disc and
macular edema as well as vessel wall staining with leakage in the posterior pole and mid-periphery, without
vitreous opacities. A diagnostic work-up for infectious, autoimmune and neoplasic conditions was negative.
Systemic immunosuppression was increased but without improvement. Sustained resolution of macular edema
was observed after intravitreal injection of dexamethasone implant and laser panretinal photocoagulation.
Conclusions: To the best of our knowledge, this is the first report of a rare ocular manifestation of familial amyloid
polyneuropathy which represents a new therapeutic challenge. Intravitreal injection of sustained release
dexamethasone implant and panretinal photocoagulation may be an effective eye-saving therapeutic approach.
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Familial amyloid polyneuropathy (FAP) or paramyloido-
sis is a heterogenous group of autosomal dominant dis-
orders characterized by extracellular amyloid deposition
in peripheral nerves, cardiac muscle, kidneys and eyes
[1]. There are three precursor proteins that can give rise
to amyloid production: transthyretin (TTR), apolipopro-
tein A-1 and gelsolin, each resulting in a distinct type of
FAP [2]. TTR-related FAP is the most frequent type and
more than 80 mutations involving this protein have been
described [3,4]. A single amino acid substitution of val-
ine for methionine at position 30 of TTR (Val30Met) is
the most frequent TTR-related FAP causing mutation* Correspondence: arnaldomiguelsantos@gmail.com
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article, unless otherwise stated.[5]. The liver is the major site of synthesis of circulating
TTR [6], but there is also evidence of TTR production
in other tissues like the retinal pigment epithelium, the
choroid plexus of the brain and the visceral yolk sac
endoderm [7]. Since 1990, liver transplantation has been
considered the main therapeutic approach, halting the
progression of neurologic complications [8]. However,
ocular complications have been reported to continue or
even increase after liver transplantation [9,10]. The
most frequently reported ocular manifestations of FAP
are keratoconjunctivitis sicca, abnormal conjunctival
vessels, pupillary abnormalities, glaucoma and vitreous
opacities [11].
The purpose of this paper is to report a case of retinal
vascular leakage including optic disc and cystoid macu-
lar edema in a patient with Val30Met TTR-related FAP.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Baseline retinography and fundus fluorescein angiography. Right eye retinography (top left) reveals no pathologic alterations. Left
eye retinography (top right) showing two dot-blot hemorrhages near the superotemporal vascular arcade, slight optic disc edema as well as
macular edema. Right eye fluorescein angiography at 2'38" reveals no changes (bottom left). Left eye fluorescein angiography at 3'37" reveals
optic disc and macular edema as well as vascular fluorescein leakage and vessel wall staining (bottom right).
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A 37-year-old Portuguese Caucasian man diagnosed
with Val30Met FAP 12 years previously presented with
painless, rapidly progressive visual loss in his left eye
(LE). He also had sensory-motor polyneuropathy,
gastrointestinal dysmotility and bradyarrhythmia which
stabilized after pacemaker implantation and liver trans-
plantation at the age of 30. He was medicated with
prednisolone (5mg/day), tacrolimus (3mg/day), siroli-
mus (2mg/day), mycophenolate mofetil (1500mg/day),
ursodeoxycholic acid and pantoprazole. There was no
other relevant past medical history. His visual acuity
was 20/20 in his right eye (RE) and 20/200 in his LE. SlitFigure 2 Baseline macular spectral domain optical coherence tomogr
right eye and cystoid macular edema in the left eye. Abbreviations: LE, leftlamp biomicroscopy was normal and intraocular pres-
sure (IOP) was 15mmHg in both eyes. A fundus exam-
ination after pupillary dilatation was normal in his RE,
whereas two dot-blot hemorrhages near his superotem-
poral vascular arcade, slight optic disc edema as well as
macular edema were identified in his LE (Figure 1). No
vitreous opacities were observed and his retinal periph-
ery was normal bilaterally. Fluorescein angiography
(FA) confirmed LE optic disc edema and showed vascu-
lar fluorescein leakage and vessel wall staining in the
posterior pole and mid-periphery, without capillary
exclusion zones or evidence of neovascularization. LE
macular edema was also evident on FA. Macular opticalaphy. The examination reveals a normal macular morphology in the
eye; RE, right eye.
Figure 3 Retinography and fundus fluorescein angiography following therapy with intravitreal bevacizumab. Right eye retinography
(top left) reveals no pathologic alterations. Left eye retinography (top right) reveals optic disc and macular edema as well as a dot-blot hemorrhage
near the inferotemporal arcade and a mid-peripheral flame-shaped hemorrhage. Right eye fluorescein angiography at 4'00" reveals staining of the optic
disc margins (bottom left). Left eye fluorescein angiography at 3'30" reveals a reduction in macular and perivascular exudation in comparison to the
previous examination; optic disc edema is also evident (bottom right).
Figure 4 Macular spectral domain optical coherence
tomography of the left eye following therapy with
intravitreal bevacizumab.
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ology in his RE and cystoid macular edema in his LE
(Figure 2).
A primary extensive work-up for systemic infectious,
autoimmune, neoplasic and inflammatory conditions was
performed including complete blood profile, chest X-ray,
serologic tests (toxoplasmosis, syphilis, human immuno-
deficiency virus, hepatitis, cytomegalovirus) and other in-
vestigations for tuberculosis (purified protein derivative
skin test and sputum analysis), fungi, acid-alcohol resistant
bacilli and bacteria. No clinically remarkable findings were
observed. Liver function tests were also unremarkable (as-
partate aminotransferase 27U/L, alanine aminotransferase
30U/L, gamma-glutamyl transferase 26U/L, alkaline phos-
phatase 132U/L, lactate dehydrogenase 421U/L, total bili-
rubin 1.30mg/dL, albumin 4.40g/dL). Brain and orbital
magnetic resonance imaging results were also normal.
Prednisolone dosage was increased to 60mg/day but
no clinical improvement was observed. This was
followed by two intravitreal injections of bevacizumab,
which resulted in slight but fugacious clinical and
functional improvement. At this time his visual acuity
was 20/20 in his RE and 20/200 in his LE. FA and OCT
revealed only a slight reduction in macular edema
and perivascular exudation in his LE (Figures 3 and 4).
The authors then decided to perform an intravitrealinjection of triamcinolone in his LE and obtained a
substantial improvement in macular edema which,
however, recurred 6 weeks after the injection. Given
the positive response to intravitreal triamcinolone,
dexamethasone intravitreal implant 0.7mg (Ozurdex®;
Allergan, Irvine, CA, USA) was performed, followed 2
weeks later by laser panretinal photocoagulation (LPP)
in his LE. One month after completing LPP, his visual
acuity was 20/20 in his RE and 20/50 in his LE. The
IOP was 16mmHg in his RE and 30mmHg in his LE;
the control of IOP was further achieved with a fixed
Figure 5 Macular spectral domain optical coherence tomography following intravitreal dexamethasone implant 0.7mg and laser
panretinal photocoagulation in the left eye. The examination reveals a complete resolution of the macular edema in the left eye. The right
eye presented normal macular morphology. Abbreviations: LE, left eye; RE, right eye.
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OCT revealed a complete resolution of macular edema
at this stage (Figure 5).
Conclusions
Here we describe unusual ocular findings in a patient
with paramyloidosis. FAP-related retinal vascular leakage
is rare and it is usually associated with amyloid vitreous
deposits, which were not observed in this patient.
Causes of ocular inflammation were excluded with an
extensive diagnostic work-up. We cannot exclude the
hypothesis of toxic microangiopathy related to drugs
such as sirolimus or tacrolimus. However, the limitation
of this reaction to the eye and the positive response to
local intravitreal therapy favors, in our opinion, the hy-
pothesis of FAP-related ocular complications. Thus, this
is probably the first report of optic disc edema, retinal
vascular leakage and cystoid macular edema in a patient
with FAP.
Amyloid deposition within the walls of retinal vessels
had been previously described. It has been hypothesized
that this impregnation may lead to retinal ischemia and
vessel wall weakening which would ultimately lead to
perivascular exudation as well as retinal and vitreous
hemorrhages [12]. O’Hearn et al. reported that vitreous
vascular endothelial growth factor (VEGF) levels in FAP
patients were raised to similar levels as those found in
patients with inactive proliferative diabetic retinopathy
[13]. Retinal neovascularization is a rare complication of
this disease, supporting the important role of VEGF up-
regulation in its pathogenesis [11]. Zou and colleagues
also reported elevated levels of VEGF in vitreous sam-
ples and in the serum of patients with ocular complica-
tions of TTR-related FAP [14]. Such elevated vitreous
VEGF levels could also account for the macular edema
observed in our patient. In this patient we observed a
positive response to both anti-VEGF and triamcinolone
intravitreal injection; however, the effect was more pro-
nounced following triamcinolone. A more sustained re-
sponse was obtained following intravitreal injection ofdexamethasone implant. To date there are no other re-
ports or studies regarding the efficacy of intravitreal
anti-VEGF or corticosteroids for the treatment of ocular
complications of FAP.
LPP therapy has been recently proposed to treat ocu-
lar complications of FAP. During 3 years of follow up,
LPP prevented the progression of vitreous and retinal
amyloid deposits in two patients [15]. After liver trans-
plantation, the retinal pigment epithelium plays the
major role in ocular amyloid production. Therefore,
the destruction of this tissue by retinal photocoagula-
tion would theoretically decrease the production of
abnormal TTR in the eye. In our patient we performed
LPP in his LE in an attempt to halt the natural history
of the disease and, at the same time, to try to reduce
the burden of intravitreal injections.
As a result of a longer life expectancy in patients with
FAP obtained with liver transplantation, more frequent and
more complex ocular complications are expected to appear
in our clinical practice. Intravitreal corticosteroid therapy in
isolation or combined with laser photocoagulation is a
promising therapeutic approach to these patients. However,
additional and larger multicenter studies are needed to
evaluate the efficacy and safety of these therapies in the
management of ocular manifestations of FAP.Consent
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